Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. - Wikidata - awgldk - TriplyDB

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

http://www.wikidata.org/entity/Q36661727

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis The Role of TLR4 in Chemotherapy-Driven Metastasis Neoplasia: the second decade.The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.Lymphangiogenesis and lymphatic metastasis in breast cancer.CXM: a new tool for mapping breast cancer risk in the tumor microenvironment.Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.Development of a mouse model for assessing fatigue during chemotherapy.BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.Role of CEACAM1, ECM, and mesenchymal stem cells in an orthotopic model of human breast cancer.Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin.Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.TLR4 is a novel determinant of the response to paclitaxel in breast cancer The War on Cancer rages on.Environmentally responsive peptides as anticancer drug carriers.Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer.The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.Role of taxanes in pancreatic cancer.Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer.mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment

P2860

Q24628746-A26E9C85-0818-4222-8E32-7424EB418841 Q26858839-2F2D3CA0-EA41-4C5D-9C0E-8CF2E3141BC9 Q26861495-7B824A09-BA7C-485C-A088-E1816C1E7A73 Q30484000-AAF85DF5-194F-4012-976B-8E419D633ED6 Q33514437-573FF6C1-1611-4F8A-ACE5-8445F700DB1C Q33916040-788C50BE-CB99-4D7A-9F0A-C85D69EF99D4 Q33940058-EE596650-08ED-45AE-8AED-D20D691B77C5 Q34586307-DA8D85BE-E199-48A9-8C9D-FCDCD93042DB Q34763649-63759CD4-A593-49CC-9B89-A5606A6D4B65 Q34819916-3EE5BE83-11DC-4A2E-AC86-9E9EFE06109B Q35066071-69BB9E99-D51E-4663-9C75-85F7FD0E6823 Q35565766-2712B82E-DBEB-4B5D-8120-2BBD7F9E912C Q35746656-B5C2250B-6943-436A-A66B-D8FE9920A4CF Q36020972-8B7A2E10-00DD-4E3D-B90B-17C8190CD8F4 Q36134678-754E8FA2-7237-40DB-9263-B3576431D963 Q36343773-61793B88-3416-499F-A583-0F3BC6625CDA Q36355240-6B7E505F-9E7A-4CAA-BB37-2994C0B5F93E Q36740744-E8D2D0DE-9E0C-4CD0-B0DD-2DD10968E953 Q36982114-E9B0228F-975E-408F-89A4-97C6BE5EE13A Q37093119-45071251-781D-44B2-8BB3-C1C702F1718A Q37478602-F3AA3749-C923-4E84-BA08-1848EDB96266 Q37560183-52E0136D-569C-4EDE-8A0A-86F6D805B691 Q37565014-8D1AB76E-72D7-45F2-B40B-87D740AEE63C Q37577978-B86D7BC2-E218-475F-BDDA-03764FFBD43C Q37743510-718FF737-F641-43D5-B4AA-4DCFE6C074E2 Q37977498-F4955681-CFD6-456F-8411-09869D313BAD Q38752236-E4EFC522-EA51-4A5B-AA07-717EBA5DF0B0 Q38878437-DC7F766A-01E8-4146-AC43-C4CC9E847167 Q39205186-97B45BD3-E90B-4FA4-B33E-F46D4911ADCE Q39816322-2A368228-6873-476A-B5E7-286A598A804A Q40368603-1155F83E-1581-4858-9325-4E7C7D319FB0 Q41133540-0D2DCD15-92FB-4E6E-AD2E-96EE16A26B51 Q42323567-6D5410EE-B1E7-4390-9134-020E7650D5FD Q47228068-6BF67061-A8AC-4B6B-A048-813007CB8B89 Q47670339-A07751C9-4CC2-4B0F-9B6F-21AB8E28CCFA Q58718463-E533D75B-DBBF-4B4C-996D-61CC8BC623E3

P2860

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

http://www.wikidata.org/entity/Q36661727

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@ast

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@en

type

label

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@ast

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@en

prefLabel

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@ast

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@en

P1433

Q36661727-6697E01B-55D6-4857-8777-C9DD7AA78A6D

P1476

Q36661727-7235C63A-2218-4C39-BFE7-70C363BA4008

P2093

Q36661727-0DBDDDDA-1358-4011-950F-EAA3106D8481

Q36661727-3E2A23EA-C55C-4935-811A-448344AF16ED

Q36661727-570BAA01-8472-4899-9516-B36549A0256B

Q36661727-5987EB63-A16C-4A9A-8B50-F9FA0BD30F3B

Q36661727-68FA491C-530B-4FC7-AF97-F7A96138ABC1

Q36661727-D3DCE560-B1F1-489C-A8BA-49E03EF24E1B

Q36661727-FEC5446B-17EC-463F-B1AE-414AF42B49D1

P2860

Q36661727-06C717FB-AF1E-40F4-B21A-A762E16DB15E

Q36661727-0CD15C67-30F6-4993-B5D4-5B1AC8EE2747

Q36661727-0DEDFD37-139C-43B3-A63D-BEDCA4486EDB

Q36661727-10681234-A948-42FB-B87B-CF74F6004E42

Q36661727-1E70E1A1-A861-4219-88C6-2AC1CD071019

Q36661727-362FCD98-A263-44D8-A722-2EEA75F0434B

Q36661727-375BF37F-FAD7-4C71-BAF1-6777B9DDA66E

Q36661727-3909A171-D768-4529-9D51-7EC6CB7E4613

Q36661727-3994D497-7ADC-49D1-9DA8-71711590DF5D

Q36661727-495B2535-346C-4B65-9ADB-2EF20FA766A8

P304

Q36661727-3F9DFB28-9FBA-4FEF-9B93-91B56184C2D3

P31

Q36661727-C739DE85-883D-4614-921B-0AE084D24863

P356

Q36661727-A4796CF6-C224-4CD0-9538-4B8469B1348A

P433

Q36661727-EAF13565-A0D9-4342-AC24-7E4319FBC54E

P478

Q36661727-749294E3-0A15-4FDD-A69D-9564EBCED077

P577

Q36661727-95C76CF7-505C-4D78-9442-18A09390633C

P5875

Q36661727-A512996B-338D-47C4-8F2E-43A4D85AD355

P698

Q36661727-A8884D87-3EC3-4CD4-A1EE-A9A7CB6DCBE7

P921

Q36661727-21037641-FEA3-4022-AEC0-91241DC2659B

P932

Q36661727-392F55C0-DC42-40B9-8043-3223F7376AF4

P356

P1433

P1476

Nab-paclitaxel efficacy in the ...... elial growth factor A therapy.

@en

P2093

Alan Stutzman

http://www.w3.org/2001/XMLSchema#string

Christopher M Bivens

http://www.w3.org/2001/XMLSchema#string

Lisa D Volk

http://www.w3.org/2001/XMLSchema#string

Michael J Flister

http://www.w3.org/2001/XMLSchema#string

Neil Desai

http://www.w3.org/2001/XMLSchema#string

Sophia Ran

http://www.w3.org/2001/XMLSchema#string

Vuong Trieu

http://www.w3.org/2001/XMLSchema#string

P2860

Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect

Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.

VEGF-mediated survivin expression in neuroblastoma cells.

Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

Endothelial cell survival and apoptosis in the tumor vasculature.

Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.

P304

613-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.08302

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5335361

http://www.w3.org/2001/XMLSchema#string

P698

18516298

http://www.w3.org/2001/XMLSchema#string

P921

P932

2386546

http://www.w3.org/2001/XMLSchema#string